BOCA RATON, Fla., Jan. 11 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals will announce 2005 fourth quarter and year- end financial results on Thursday, February 23, 2006, after market close. The company will also host a live webcast at 4:30 p.m. ET.
The live webcast can be accessed at http://audioevent.mshow.com/284694 or via the Nabi Biopharmaceuticals website at http://www.nabi.com . If you do not have Internet access, the U.S./Canada call-in number is 877-569-0953 conference code 4182747, and the international call-in number is 706-634-4967 conference code 4182747. An audio replay will be available for U.S./Canada callers at 800-642-1687 conference code 4182747, and for international callers at 706-645-9291 conference code 4182747.
An archived version of the webcast will be available at the same Internet address through March 2, 2006. The audio replay will also be available through March 2, 2006. The press release will be available on the company’s website at http://www.nabi.com .
Nabi Biopharmaceuticals also announced today that its Annual Meeting of Shareholders will be held on Friday, May 12, 2006, in Boca Raton, Florida, at 10:00 a.m. ET at the Renaissance Boca Raton Hotel, Coral Ballrooms B, C and D, 2000 NW 19th Street (Phone: 561-388-5252).
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are focusing on developing products addressing commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and pre-clinical development. The company also filed Marketing Authorization Applications (MAA) in Europe to market Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the prevention of hepatitis B disease in HBV-positive liver transplant patients; and for PhosLo, which is already marketed in the United States. The company’s products in development include NicVAX, a vaccine to treat nicotine addiction, and Civacir, an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our Website: http://www.nabi.com .
Audio: http://audioevent.mshow.com/284694Nabi Biopharmaceuticals
CONTACT: Constance C. Bienfait, Vice President, Investor Relations, NabiBiopharmaceuticals, +1-561-989-5800
Web site: http://www.nabi.com/
